How FDA supplement warning letters actually work

An FDA warning letter is a public, dated document telling a specific company that the agency considers a specific product in violation of federal law — most often because marketing claims turned the product into an unapproved drug. The letters do not order a recall and do not fine anyone. They start a compliance clock, and they are published in full on the FDA's website, which makes them one of the few primary-source windows into supplement enforcement.

24 News Click publishes information, not medical advice. This article explains a regulatory mechanism using dated public documents; it is not legal advice.

What triggers a supplement warning letter?

The most common trigger is a disease claim. Under the Dietary Supplement Health and Education Act of 1994, per the FDA and the National Institutes of Health Office of Dietary Supplements, supplements may carry structure-and-function claims but may not claim to treat, cure, mitigate or prevent a disease. When a product's website or label says it treats diabetes, cardiovascular disease or arthritis, the FDA's position is that the product is being sold as an unapproved new drug. The second trigger is adulteration — an ingredient not lawfully marketable in supplements, such as novel synthetic stimulants, or an ingredient making the product unsafe under the agency's standards.

Both triggers appear repeatedly in the public record. Per the FDA's constituent update of July 2021, the agency and the FTC jointly sent warning letters to ten companies selling supplements claimed to treat diabetes. Per the FDA's announcement of November 17, 2022, seven companies received letters over claims to treat cardiovascular disease.

What does a warning letter actually require?

The letters follow a standard structure, visible in every published example. The agency cites the specific claims, usually quoting website text, identifies the statutory violations, and gives the company 15 working days to respond in writing describing corrective steps. The letter states that failure to correct the violations may result in further enforcement — seizure, injunction or criminal prosecution. In practice, most companies rewrite their marketing and the file closes quietly; a smaller number of cases escalate, and the escalation documents are public too.

A warning letter is not a finding by a court. It is the agency's stated position, and companies dispute them. But for a reader evaluating a product, a warning letter is a documented statement from the regulator that the marketing crossed a legal line — a fact about the product's history that label copy will never volunteer.

Why don't the letters pull products from shelves?

The enforcement architecture is post-market by design. The FDA can request a voluntary recall and can seize products through the courts, but a warning letter itself removes nothing. Per the agency's own enforcement descriptions, the sequence runs from inspection and letter to escalated action only if violations continue. That is why a supplement can stay on sale for months after a public warning letter about it — a gap consumers often find surprising and the agency's critics cite routinely. The practical consequence for readers: the absence of a recall does not mean the absence of a documented violation.

How can a reader use the letters directly?

The FDA maintains a searchable warning-letter database, and its dietary-supplement section lists letters by company and date. The Council for Responsible Nutrition, an industry trade group, also maintains a searchable database of supplement-related warning letters. Checking a brand in either database before buying takes minutes and answers a narrow, useful question: has the regulator formally told this company its marketing or formulation broke the law, and when?

The letters also serve as a map of where enforcement attention flows. Across recent years, the recurring themes are consistent: disease claims in categories preying on serious conditions — diabetes, heart disease, cancer — and adulteration in weight-loss, sexual-enhancement and pre-workout products, where undeclared pharmaceutical ingredients have appeared. Per the FDA's public health notifications, some weight-loss and male-enhancement products sold online have contained undeclared prescription-drug ingredients, which is a drug-adulteration problem rather than a labeling dispute.

What a warning letter does not tell you

A warning letter does not certify that every other product from the same company is compliant. It does not measure the product's contents, and it does not judge whether the ingredient works as marketed — that is an evidence question, separate from the legal one. Conversely, a company with no letters is not thereby trustworthy; enforcement is spotty and resource-limited, per the agency's own budget documents. The letters are a floor of documented information, not a ceiling.

What do warning letters look like on the page?

The letters are formulaic by design, and the format is itself information. They open with the facility's inspection history, quote the offending claims verbatim from websites and labels, walk through each statutory violation with citations to the Food, Drug, and Cosmetic Act, and close with the response deadline and the escalation warning. Because claims are quoted exactly, a reader can compare the company's marketing language with the agency's characterization and judge for themselves. The letters also list the specific products named, which means a warning letter about one SKU says nothing directly about the company's others — a nuance both critics and marketers routinely flatten.

Do warning letters change company behavior?

Usually, at the level of marketing language. The publicly observable pattern is that most recipients revise websites and labels rather than fight, partly because the letter starts a documented record that makes later enforcement easier for the agency. A smaller set of companies treats letters as negotiable, responding with counsel and sometimes contesting the science. And a recurring fringe simply relabels or rebrands, which is why the agency's docket keeps returning to the same product categories — weight-loss, sexual enhancement, and disease-cure claims aimed at serious conditions — year after year. The letters are best read not as a cleanup operation that completes, but as a running public log of where the agency draws lines.

What should a reader take from the July 2021 and November 2022 examples?

The two dated cases illustrate the letters' scope and their limits. In the July 2021 action, per the FDA's constituent update, the joint letters with the FTC combined drug-claim violations with deceptive-advertising exposure — the two regulators' overlapping jurisdiction doubling the pressure on the recipients. In the November 17, 2022 cardiovascular action, the agency cited claims about treating atherosclerosis, high cholesterol and hypertension, and noted that consumers relying on such products might delay proven treatment. That second theme — delayed care, not just false labeling — is the agency's stated rationale for prioritizing disease claims over other violations, and it is the reason warning letters are a consumer-safety document and not only a compliance one.

FAQ

Does an FDA warning letter mean a supplement was recalled?

No. A warning letter notifies a company of violations and starts a 15-working-day response clock. Recalls are separate actions, usually voluntary, and many warned products remain on sale while marketing is corrected.

Where are warning letters published?

On the FDA's public warning-letter database, organized by company and date, with supplement-related letters additionally listed under the agency's food and dietary-supplements section. Trade databases, such as the one run by the Council for Responsible Nutrition, mirror the record.

Why do most supplement warning letters cite drug claims?

Because disease claims legally convert a supplement into an unapproved new drug under the 1994 framework. Saying a product treats diabetes or heart disease triggers that reclassification, which is why claim language, not the ingredient itself, drives most letters.